APR 2 8 2004

1.4 510(k) Summary of Safety and Effectiveness

Submitted by: Elizabeth J. Mason

Sr. Regulatory Affairs Specialist

Address: Nobel Biocare USA Inc.

22715 Savi Ranch Parkway Yorba Linda, CA 92887

Telephone: (714) 282-4800, ext. 7830

Facsimile: (714) 998-9348

Date of Submission: March 3, 2004

Classification Name: Endosseous Implant (21 CFR 872.3640)

Trade or Proprietary

or Model Name: Nobel Biocare Permanent Centric Post

Legally Marketed Device(s): Nobel Biocare Centric Post (K033724)

Device Description:

Nobel Biocare's Permanent Centric Post is a hollow, accessory component designed to enhance the performance of the implant/abutment system by ensuring proper alignment between an abutment and an endosseous implant, while additionally acting as a seal that prevents fluids from seeping into the implant interior.

The Nobel Biocare Permanent Centric Post does not contact any mucous membranes in the oral cavity because it rests inside the implant/abutment interface. The Centric Post can only be used as part of the implant system, not on its own. It is designed to remain inside the implant/abutment interface for as long as the implant remains in the patient's mouth.

Indications for Use:

The Nobel Biocare Permanent Centric Post is a support component indicated for use as both an alignment post to center an abutment, and as a seal to prohibit fluids from seeping into the implant interior.

The Nobel Biocare Permanent Centric Post is a component within the implant system, and is intended for use in permanent restorations in order to restore the chewing function of fully edentulous and/or partially edentulous patients.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 2 8 2004

Ms. Elizabeth J. Mason Senior Regulatory Affairs Specialist Nobel Biocare USA, Incorporated 22715 Savi Ranch Parkway Yorba Linda, California 92887

Re: K040573

Trade/Device Name: Nobel Biocare Permanent Centric Post, Models 31234, 31235

Regulation Number: 872.3640

Regulation Name: Endosseous Implant

Regulatory Class: III Product Code: NHA Dated: March 3, 2004 Received: March 9, 2004

Dear Ms Mason:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if k	nown):	. •			
Device Name: Not	el Biocare Perm	anent Centric P	ost		
Indications For Use):				
The Nobel Biocare I post to center an ab	Permanent Centric Foutment, and as a se	Post is a support co eal to prohibit fluids	imponent indicated from seeping into t	for use as both an alig he implant interior.	nment
The Nobel Biocare intended for use in pand/or partially eder	permanent restoration	Post is a componer ons in order to resto	nt within the endoss ore the chewing fun	eous implant system, a ction of fully edentulou	and is s
Prescription Use (Part 21 CFR 801 Sub	X part D)	AND/OR	Over-The-Co (21 CFR 807 S	unter Use ubpart C)	
(PLEASE DO NO NEEDED)	T WRITE BELO	W THIS LINE-C	ONTINUE ON A	NOTHER PAGE II	Ξ
					_
Cor	ncurrence of CDF	RH, Office of De	vice Evaluation	(ODE)	
ă	Livit SBetz () Division Sign-Off)	0128 for Dr.	<u>Susa</u> nKeen	ner	
Ď	Division Sign-On/ Division of Anesthes Infection Control, De	siology, General H ental Devices	ospital,	Page 1 of _1	

510(k) Number: